Treatment patterns, economic burden, and overall survival in US Medicare Advantage beneficiaries newly diagnosed with acute myeloid leukemia (AML) in 2015–2020

Abstract

The present study assessed changes in patient management, economic burden, and overall survival (OS) in a contemporary cohort of 2775 US Medicare Advantage beneficiaries aged ≥66 years newly diagnosed with acute myeloid leukemia (AML) between 01 January 2015 and 30 June 2020. Use of venetoclax-based therapy increased and replaced hypomethylating agent (HMA) monotherapy as the most common first-line treatment choice in 2019–2020. In newly diagnosed AML patients aged ≥75 and 66–74 years, mean per-patient 1-year healthcare expenditures were $81,818 and $156,033 (2020 USD) and median OS was 2.3 and 8.5 months, respectively. In addition, 40% of Medicare Advantage patients with newly diagnosed AML continue to receive supportive care alone. These findings indicate that at the population level clinical outcomes remain poor for older adults with AML, pointing to a continuing unmet medical need.

Keywords:

• Acute myeloid leukemia
• older adults
• treatment patterns
• economic burden of disease
• overall survival
• healthcare resource utilization

Acknowledgements

The authors thank Christopher Pericone (Janssen Pharmaceuticals) and Leo J. Philip Tharappel (SIRO Clinpharm Pvt Ltd) for providing editorial assistance.

Disclosure statement

SFH reports consulting on unrelated project/research for Tyme Inc, AstraZeneca, Janssen, AbbVie, Novartis, BeiGene, Genentech, Flatiron Health, and Bayer; MPI, RW, and EA are employees of Janssen Scientific Affairs, LLC; LO is an employee of Janssen Research & Development, LLC; AS is an employee of Mu Sigma who received funding for study conductance.

Additional information

Funding

This work was supported by Janssen Pharmaceuticals. SFH received funding from Janssen Scientific Affairs, LLC for data acquisition, medical writing assistance, and article processing charges.